Following latest news of drug failure, Lilly faces investor questions about growth
This article was originally published in Scrip
Executive Summary
After announcing its latest clinical disappointment, Eli Lilly will face a number of questions this week about how it is going to remain profitable by cutting more expenses or finding strategic deals that can quickly add to sales.